© 2020 MJH Life Sciences and OncLive. All rights reserved.
August 11th 2020
Jennifer Woyach, MD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.
Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses treatment considerations in triple-negative breast cancer.
Bradley J. Monk, MD, FACS, FACOG, discusses emerging therapies in cervical cancer.
Hung Khong, MD, discusses the potential benefit of combining immunotherapy with endocrine therapy in estrogen receptor–positive, HER2-negative breast cancer.
Betsy O'Donnell, MD, discusses ongoing research efforts in multiple myeloma.
John A. Abraham, MD, FACS, discusses key considerations regarding the management of tenosynovial giant cell tumor.
August 10th 2020
Matthew S. Davids, MD, MMSc, discusses remaining questions with umbralisib plus ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma.
Paolo Ghia, MD, PhD, discusses overall survival data with acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND trial.
Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast cancers.
Ruben A. Mesa, MD, discusses racial disparities in clinical trials for patients with myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.